Close Menu

NEW YORK – Nanomix said Wednesday it has been awarded up to about $570,000 in funding from the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) to support development of COVID-19 point-of-care assays that will run on the Nanomix eLab analyzer.

The assays detect either SARS-CoV-2 antigens or antibodies to SARS-CoV-2 to identify active infections and previous exposure, the Emeryville, California-based firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.